Call for Paper - January 2023 Edition
IJCA solicits original research papers for the January 2023 Edition. Last date of manuscript submission is December 20, 2022. Read More

In silico Analysis of Binding Interaction of Antiepileptic Drugs with GABA Receptor Associated Protein of Caenorhabditis elegans

Print
PDF
IJCA Proceedings on National Seminar on Application of Artificial Intelligence in Life Sciences 2013
© 2013 by IJCA Journal
NSAAILS - Number 1
Year of Publication: 2013
Authors:
Suchi Smita

Suchi Smita. Article: In silico Analysis of Binding Interaction of Antiepileptic Drugs with GABA Receptor Associated Protein of Caenorhabditis elegans. IJCA Proceedings on National Seminar on Application of Artificial Intelligence in Life Sciences 2013 NSAAILS(1):29-36, February 2013. Full text available. BibTeX

@article{key:article,
	author = {Suchi Smita},
	title = {Article: In silico Analysis of Binding Interaction of Antiepileptic Drugs with GABA Receptor Associated Protein of Caenorhabditis elegans},
	journal = {IJCA Proceedings on National Seminar on Application of Artificial Intelligence in Life Sciences 2013},
	year = {2013},
	volume = {NSAAILS},
	number = {1},
	pages = {29-36},
	month = {February},
	note = {Full text available}
}

Abstract

Malfunctioning of synaptic vesicle in the absence of some essential regulatory proteins causes a significant decrease in the level of neurotransmitters like gamma-amino butyric acid (GABA) leading to epilepsy. In the present work, GABA receptor associated protein (GABARAP), being the major inhibitory neurotransmitter receptor from C. elegans, is investigated for its efficacy with various antiepileptic drugs. These drugs interact with the binding site of GABA receptor and regain the normal level of the inhibitory neurotransmitter, GABA. These inhibitors play a crucial role in controlling the expression of the neurotransmitter receptor at the postsynaptic membrane. Our results shows that out of the various drugs docked at the binding site, Vigabatrin and Pregablin came up with the highest score thereby proving them to be effective in the treatment of the neurological disorder.

References

  • [No authors listed], (1993). Commission on Epidemiology and Prognosis, International League against Epilepsy. "Guidelines for epidemiologic studies on epilepsy. Commission on Epidemiology and Prognosis, International League against Epilepsy", Epilepsia, 34, 4, 592–6.
  • Blume, W. , Lüders, H. , Mizrahi, E. , Tassinari, C. , van Emde Boas, W. , Engel, J. (2001). "Glossary of descriptive terminology for ictal semiology: report of the ILAE task force on classification and terminology", Epilepsia, 42, 9, 1212–8.
  • Amadou, G. D. , Hanneke, M. de. B. , Custodia, M. , Leonid, P. and Harry, M. (2003). The global campaign against epilepsy in Africa,Acta Tropica,87, 149-159.
  • Steiger, J. L. and Russek, S. J. (2004). "GABAA receptors: building the bridge between subunit mRNAs, their promoters, and cognate transcription factors", Pharmacology & Therapeutics, 101, 3, 259-281.
  • Baulac, S. et al. (2001). First genetic evidence of GABAA receptor dysfunction in epilepsy: a mutation in the gamma2-subunit gene, Nat. Genet. , 28, 46–48.
  • Cossette, P. et al. (2002). Mutation of GABRA1 in an autosomal dominant form of juvenile myoclonic epilepsy, Nat. Genet. , 31, 184–189.
  • Wallace, R. H. et al. (2001). Mutant GABAA receptor gamma2-subunit in childhood absence epilepsy and febrile seizures, Nat. Genet. , 28, 49–52.
  • McIntire, S. L. et al. (1997). Identification and characterization of the vesicular GABA transporter, Nature, 389, 870–876.
  • Docherty, M. et al. (1985). Evidence for specific immunolysis of nerve terminals using antisera against choline acetyltransferase, glutamate decarboxylase, and tyrosine hydroxylase, Brain Res. , 339, 105–113.
  • Treiman, D. M. (2001). GABAergic mechanisms in epilepsy, Epilepsia, 42, 3, 8-12.
  • Chen, Z. W. and Olsen, R. W. (2007). GABAA receptor associated proteins: a key factor regulating GABAA receptor function, J Neurochem. , 100(2), 279-94.
  • Bamber, B. A. , Beg, A. A. , Twyman, R. E. , Jorgensen, E. M. (1999). The Caenorhabditis elegans unc-49 locus encodes multiple subunits of a heteromultimeric GABA receptor, J. Neurosci. ,19,5348–5359.
  • Richmond, J. E. , Jorgensen, E. M. (1999). One GABA and two acetylcholine receptors function at the C. elegans neuromuscular junction, Nat. Neurosci. , 2, 791–797.
  • Wardell, B. , Marik, P. S. , Piper, D. , Rutar, T. , Jorgensen, E. M. , Bamber, B. A. (2006). Residues in the first transmembrane domain of the Caenorhabditis elegans GABAA receptor confer sensitivity to the neurosteroid pregnenolone sulfate, British Journal of Pharmacology, 148, 162-172.
  • Wang, H. and Olsen, R. W. (2000). Binding of the GABAA receptor-associated protein (GABARAP) to microtubules and microfilaments suggests involvement of the cytoskeleton in GABARAP-GABAA receptor interaction, J Neurochem, 75, 644eC655.
  • Anhut, H. , Ashman, P. , Feuerstein, T. J. , Sauermann, W. , Saunders, M. , Schmidt, B. (1994). Gabapentin (Neurontin) as add-on therapy in patients with partial seizures: a double-blind, placebo-controlled study. The International Gabapentin Study Group, Epilepsia, 35,795-801.
  • Sivenius, J. , Kalviainen, R. , Ylinen, A. , Riekkinen, P. (1991). Double blind study of gabapentin in the treatment of partial seizures, Epilepsia, 32, 539-42.
  • [No authors listed], (1990). Gabapentin in partial epilepsy. UK Gabapentin Study Group, Lancet, 335, 1114-7.
  • [No authors listed], (1993). Gabapentin as add-on therapy in refractory partial epilepsy: a double-blind, placebo-controlled, parallel-group study. US Gabapentin Study Group No 5, Neurology, 43, 2292-8.
  • Matsuo, F. , Bergen, D. , Faught, E. , Messenheimer, J. A. , Dren, A. T. , Rudd, G. D. , et al. , (1993). Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. US Lamotrigine Protocol 0. 5 Clinical Trial Group, Neurology, 43, 2284-91.
  • Binnie, C. D. , Debets, R. M. , Engelsman, M. , Meijer, J. W. , Meinardi, H. , Overweg, J. , et al. ,(1989). Double blind crossover trial of lamotrigine (Lamictal) as adds on therapy in intractable epilepsy, Epilepsy Res, 4, 222-9.
  • Jawad, S. , Richens, A. , Goodwin, G. , Yuen, W. C. (1989). Controlled trial of lamotrigine (Lamictal) for refractory partial seizures, Epilepsia, 30, 356-63.
  • Loiseau, P. , Yuen, A. W. , Duche, B. , Menager, T. , Arne Bes, M. C. (1990). A randomised double blind placebo controlled crossover adds on trial of lamotrigine in patients with treatment resistant partial seizures, Epilepsy Res, 7, 136-45.
  • Messenheimer, J. , Ramsay, R. E. , Willmore, L. J. , Leroy, R. F. , Zielinski, J. J. , Mattson, R. , et al. (1994). Lamotrigine therapy for partial seizures: a multicenter, placebo-controlled, double-blind, cross-over trial, Epilepsia, 35, 113-21.
  • Schapel, G. J. , Beran, R. G. , Vajda, F. J. , Berkovic, S. F. , Mashford, M. L. , Dunagan, F. M. , et al. (1993). Double blind, placebo controlled crossover study of lamotrigine in treatment resistant partial seizures, J Neurol Neurosurg Psychiatry, 56, 448-53.
  • Smith, D. , Baker, G. , Davies, G. , Dewey, M. , Chadwick, D. W. (1993). Outcomes of add on treatment with lamotrigine in partial epilepsy, Epilepsia, 34, 312-22.
  • Tassinari, C. A. , Michelucci, R. , Chauvel, P. , Chodiewicz, J. , Shorvon, S. , Henriksen, O. , et al. (1996). Double blind placebo controlled trial of topiramate (600 mg daily) for the treatment of refractory partial epilepsy, Epilepsia, 37, 763-8.
  • Ben-Menachem, E. , Henriksen, O. , Dam, M. , Schmidt, D. (1996). Double blind placebo controlled trial of topiramate as add-on treatment in patients with refractory partial epilepsy, Epilepsia, 36, 539-43.
  • Faught, E. , Wilder, B. J. , Ramsay, E. , Reife, R. , Kramer, L. , Pledger, G. , et al. (1996). Topiramate controlled dose ranging trial in refractory partial epilepsy using 200, 400 and 600 mg daily dosages, Neurology, 46, 1684-90.
  • Privitera, M. , Fincham, R. , Renry, J. , Reife, R. , Kramer, L. , Pledger, G. , et al. (1996). Topiramate placebo controlled trial in refractory partial epilepsy using 600, 800 and 1000 mg daily dosages, Neurology, 46, 1678-83.
  • French, J. A. , Mosier, M. , Walker, S. , Somerville, K. , Sussman, N. (1996). A double-blind, placebo controlled study of vigabatrin 3g/day in patients with uncontrolled complex partial seizures, Neurology, 46, 54-61.
  • Grunewald, R. A. , Thompson, P. J. , Corcoran, R. , Corden, Z. , Jackson, G. D. , Duncan, J. S. (1994). Effects of vigabatrin on partial seizures and cognitive function, J Neurol Neurosurg Psychiatry, 57, 1057-63.
  • Harris,T. W. , Chen,N. , Cunningham,F. , Tello-Ruiz,M. , Antoshechkin,I. , Bastiani,C. , Bieri,T. , Blasiar,D. , Bradnam,K. , Chan,J. et al. (2004). WormBase: a multi-species resource for nematode biology and genomics, Nucleic Acids Res. , 32 (Database issue), D411–D417.
  • Harris,T. W. , Lee,R. , Schwarz,E. , Bradnam,K. , Lawson,D. , Chen,W. , Blasier,D. , Kenny,E. , Cunningham,F. , Kishore,R. et al. (2003). WormBase: a cross-species database for comparative genomics, Nucleic Acids Res. , 31, 133–137.
  • Pattanayak, M. , Seth, P. K. , Smita, S. , Gupta, S. K. (2009). Geraniol and Limonene interaction with 3-hydroxy-3-methylgluraryl-CoA (HMG-CoA) reductase for their role as cancer chemo-preventive agents. , J Proteom and Bioinfo, 2(11), 466-474.